Clinical Evaluation Of LeSoleil Against COVID-19


Announcement on Global Recruitment of Collaborative
Agencies for LeSoleil

Guangzhou, China, Jan 6, 2022 –
(ACN Newswire) – Since February 2020, when Suntrap Life
Technologies Ltd established a COVID-19 project for drug
discovery, the Suntrap research team has evaluated and
prudently predicted the characteristics of COVID-19.
Utilizing the proprietary S-CPDD drug design and discovery
system and IDDNU(R) (International Drug Design Network
Union) platforms in accordance with scientific laws of drug
discovery, Suntrap’s research team has tracked and analyzed
the pathological characteristics, clinical needs,
pathogenesis research and social demands of patients. In
terms of the determination of the direction of drug research
and development (R&D), COVID-19 drug related targets
acquisition, molecular design and screening, and preclinical
verification, the new drug R&D in the Suntrap research
team is fully guided by clinical values. It will be standard
for the Suntrap team to quickly transform biomedical
research into industrial products, and ultimately develop
new pharmaceutical products that benefit the public, thus
realizing the fundamental significance of new drug
R&D.

The Suntrap team believes that the
prevention and treatment of COVID-19 should focus on the
development of multi-targeted and broad-spectrum
anti-coronavirus drugs.

In May 2020, the
Suntrap research team identified a lead compound
“LeSoleil-T” through a series of bioassays, which showed
anti-coronavirus activities with multi-targets inhibition
effects. Further studies revealed that the multi-targets
design properties of LeSoleil-T could meet the demands of
broad-spectrum anti-coronavirus.

In view of the
inhibitory effects of LeSoleil-T against SARS-CoV-2, the
pharmacological mechanisms of LeSoleil-T were explored
through a series of experimental assays. The results showed
that LeSoleil-T has pharmacological effects in the treatment
of SARS-CoV-2 infection as the following: broad-spectrum
anti-coronavirus inhibitory effects, anti-inflammatory
effects, neuron protections, delay and reversal of tissue
fibrosis.

Based on the above results, the Suntrap team
has obtained the Chinese invention patent authorization for
the broad-spectrum anti-coronavirus in January 2021, and has
filed international patent applications through the PCT, and
applied for patent protection in many countries and
regions.

According to clinical investigations, upon
SARS-CoV-2 infection, the levels of the neutrophil count,
D-dimer, blood urea and creatinine in patients will increase
continuously, while the count of lymphocytes will continue
to decline until death. The Suntrap team found that
LeSoleil-T could eliminate inflammation induced by
SARS-CoV-2 infection. The anti-inflammatory effects of
LeSoleil-T are mainly to inhibit proinflammatory factor
expression and reduce oxidative stress responses. Firstly,
LeSoleil-T can inhibit neutrophil aggregation to reduce the
production of 4-HNE (4-hydroxynonenal) by oxidative stress
response, which leads to the reduction of the lipid
peroxidation end-product formation, and finally, contribute
to its anti-inflammatory activity. Secondly, LeSoleil-T
directly inhibits the expression of proinflammatory factors
(e.g., Tnf-, IL-1, IL-6, Mcp-1, Mcp-2, and Mip-1).
Finally, it activates the interactions among PGC-1
(Peroxisome proliferator-activated receptor- coactivator),
Nrf1 (Nuclear Respiratory Factor 1) and Nrf2 (Nuclear
Respiratory Factor 2) to regulate the mitochondrial
synthesis, respiration, and various antioxidant enzymes.
Meanwhile, the Nrf2/ARE (antioxidant response element)
complex scavenges free radicals by regulating the expression
of HO-1 (heme oxygenase-1).

Based on the clinical
symptoms and pathogenic mechanism of patients infected with
SARS-CoV-2, the Suntrap research team optimized and
developed different clinical protocols. The basic
formulation was completed in November 2020.

The
LeSoleil broad-spectrum anti-coronavirus protective and
therapeutic spray is portable and easy to use. It
effectively prevents healthy people from infection and
blocks the spread of SARS-CoV-2 from asymptomatic and mild
COVID-19 patients. LeSoleil broad-spectrum anti-coronavirus
protective and therapeutic spray can cope with the
prevention and treatment of SARS-CoV-2 and variant strains
(e.g., Delta and Omicron.). In addition, the preclinical
study conducted by the Suntrap team revealed that LeSoleil
can also be used for upper respiratory tract infections
caused by influenza viruses and mutant strains (e.g., H1N1,
H5N1, H7N1, H7N2, H7N3, H7N7, H7N9, H9N2 and H10N8). The new
corresponding symptoms still need to be verified by clinical
research.

The COVID-19 pandemic has continued for
nearly two years. Mutant strains are constantly emerging,
and the global incidence rate continues to rise. To date,
the Suntrap research team has achieved a certain degree of
breakthrough in the design of multi-target anti-coronavirus
drugs. It is necessary to accelerate the clinical
verification and strengthen cooperation. To further in-depth
clinical research of LeSoleil anti-SARS-CoV-2 drugs, and
deter COVID-19 as an obstacle for social stability, economic
development and human health, Suntrap recruits qualified
clinical research institutions around the world to carry out
clinical revalidation studies on the efficacy of the
LeSoleil broad-spectrum anti-coronavirus drug series against
mutant strains of SARS-CoV-2.

Consult www.suntrap.com
or search for “IDDNU” and “Suntrap” for related
reports.

Full release at https://www.suntrap.com/newsinfo/586652.html?templateId=182930

© Scoop Media

 



Source link

Leave a Comment

x